LOXO-338 is under clinical development by Loxo Oncology and currently in Phase I for B-Cell Chronic Lymphocytic Leukemia. According to GlobalData, Phase I drugs for B-Cell Chronic Lymphocytic Leukemia have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LOXO-338’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LOXO-338 overview
LOXO-338 is under development for the treatment of advanced hematological malignancies including B-cell chronic lymphocytic leukemia, follicular lymphoma, marginal zone b-cell lymphoma, non-hodgkin lymphoma, multiple myeloma (Kahler disease), Waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma) and mantle cell lymphoma. It is administered through oral route and acts by targeting apoptosis regulator Bcl 2 (BCL2).
Loxo Oncology overview
Loxo Oncology a biopharmaceutical company that carries out the development of targeted small molecule therapeutics for the treatment of cancer. The company’s pipeline products include FGFR3 SELECTIVE, PI3Ka INIBITOR, 225Ac-PSMA-62 PNT2001, 225Ac-PSMA-62 PNT2001, NECTIN-4 ADC 1 are for the treatment of cancer; OLOMORASIB: KRAS G12C treats mutant non small cell lung cancer (NSCLC); ABEMACICLIB targets metastatic breast cancer (MBC) sequencing; SELPERCATINIB treats adjuvant RET+ non small cell lung cancer (NSCLC); IMLUNESTRANT for ER+ HER2 metastatic breast cancer (mBC) and adjuvant breast cancer; PIRTOBRUTINIB for relapsed/refractory chronic lymphocytic leukemia (CLL) combination, 1L chronic lymphocytic leukemia (CLL) monotherapy. Loxo Oncology is headquartered in Stamford, Connecticut, the US.
For a complete picture of LOXO-338’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
